This product is a recombinant mouse specific anti-Dengue virus-1 monoclonal antibody. 7F4 recognizes an epitope on the envelope protein containing E118 (domain II). It has a neutralizing activity 10- to 1,000-fold stronger than previously reported neutralizing MAbs targeting domain I and/or domain II. Induction of these antibody species 7F4 in immunized mice may have implications for dengue vaccine strategies to minimize induction of enhancing antibodies in vaccinated humans.
Figure 1 Neutralizing and enhancing activities of DENV-1 MAbs.
Balance between neutralizing and enhancing activities of five DENV-1 MAbs obtained in our assay system using semiadherent K562 cells. C(+), presence of complement; C(−), absence of complement; Ave, average.
A Mouse Monoclonal Antibody against Dengue Virus Type 1 Mochizuki Strain Targeting Envelope Protein Domain II and Displaying Strongly Neutralizing but Not Enhancing Activity
Figure 2 Effect of the IgG subclass or epitope site on the balance of neutralizing activity and enhancing activity.
The balances were compared among four antibodies of different IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) engineered from 7F4 (closed circles) or 3H12 (open circles) in the absence.
A Mouse Monoclonal Antibody against Dengue Virus Type 1 Mochizuki Strain Targeting Envelope Protein Domain II and Displaying Strongly Neutralizing but Not Enhancing Activity
Figure 3 Epitope-blocking ELISA to examine human sera possessing neutralizing activity against DENV-1 for the presence of an antibody sharing an epitope with 7F4.
Dose-dependent percent inhibition curves obtained with four Indonesian serum samples with neutralizing antibody titers of 1:160 (closed circles), 1:320 (open circles), 1:1,280 (open squares), and 1:5,120 (closed squares).
A Mouse Monoclonal Antibody against Dengue Virus Type 1 Mochizuki Strain Targeting Envelope Protein Domain II and Displaying Strongly Neutralizing but Not Enhancing Activity
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-1088LC-S(P) | Anti-DENV1 E Recombinant Antibody scFv Fragment (15C12) | ELISA | Mouse Antibody |
MRO-1089LC-S(P) | Anti-DENV1 E Recombinant Antibody scFv Fragment (9B1) | ELISA | Mouse Antibody |
MRO-1090LC-S(P) | Anti-DENV1 E Recombinant Antibody scFv Fragment (8F6) | ELISA | Mouse Antibody |
MRO-1091LC-S(P) | Anti-DENV1 E Recombinant Antibody scFv Fragment (3C9) | ELISA | Mouse Antibody |
MRO-1092LC-S(P) | Anti-DENV1 E Recombinant Antibody scFv Fragment (7F4) | ELISA | Mouse Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MRO-1104LC-F(E) | Human Anti-DENV1 E Recombinant Antibody; Fab Fragment (MRO-1104LC-F(E)) | ELISA | Human Fab |
MRO-1105LC-F(E) | Human Anti-DENV1 E Recombinant Antibody; Fab Fragment (MRO-1105LC-F(E)) | ELISA | Human Fab |
MRO-1111LC-F(E) | Human Anti-DENV1 E Recombinant Antibody; Fab Fragment (MRO-1111LC-F(E)) | ELISA | Human Fab |
MRO-1112LC-F(E) | Human Anti-DENV1 E Recombinant Antibody; Fab Fragment (MRO-1112LC-F(E)) | ELISA | Human Fab |
MRO-1123LC-F(E) | Human Anti-DENV1 E Recombinant Antibody; Fab Fragment (MRO-1123LC-F(E)) | ELISA | Human Fab |
There are currently no Customer reviews or questions for MRO-1092LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.